Cholesterol, total; Apolipoprotein B (ApoB); DRI; GlycA; high-density lipoprotein (HDL) cholesterol; low-density lipoprotein (LDL) cholesterol (calculation); non-high-density lipoprotein (non-HDL) cholesterol (calculation = total cholesterol minus HDLC); triglycerides
1 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Apolipoprotein B (ApoB): Refining Cardiovascular Risk Management and LDL Treatment Decisions
Serum, shipped refrigerated or plasma
0.5 mL (Note: This volume does not allow for repeat testing.)
Plain red-top tube (preferred); NMR LipoTube (black-and- yellow-top tube), lavender-top (EDTA-no gel) tube, or green-top (heparin-no gel) tube is acceptable.
Collect specimen in plain red-top tube (no gel), which is the preferred specimen. Hold tube upright at room temperature for 45 minutes and allow to clot. Centrifuge specimen after clotting according to manufacturer's specifications. Transfer to a transport tube for storage at (2°C to 8°C) until shipped.
For NMR LipoTube (black-and-yellow-top tube), keep upright at room temperature for 30 minutes and allow to clot. Centrifuge at 1800 to 2200xg for 10 to 15 minutes immediately after clotting. If the sample cannot be centrifuged immediately, it must be refrigerated at (2°C to 8°C) and centrifuged within 24 hours of collection. The NMR tube should then be stored at (2°C to 8°C) until shipped.
Separate plasma from lavender-top (EDTA-no gel) tube or green-top (heparin-no gel) tube immediately after collection and transfer to a plastic transport tube for shipment to the laboratory.
Serum or plasma drawn in gel-barrier collection tubes other than the NMR LipoTube should not be used.
LipoTube Serum: 1 day; Plain Serum: 1 day; EDTA Plasma: 8 hours; Sodium Heparin Plasma: 8 hours
LipoTube Serum: 8 days; Plain Serum: 8 days; EDTA Plasma: 8 days; Sodium Heparin Plasma: 7 days
All tubes: 14days (Note: Triglyceride values in frozen samples with high values >400 mg/dL may be decreased more than 10% when frozen.)
Patient fasting is not required; however, in conditions where triglyceride values provide a priori diagnostic information, such as screening for familial hypercholesterolemia or early onset heart disease, pancreatitis, or confirming hypertriglyceridemia, the patient should be counseled to fast 12 to 14 hours prior to blood draw.
Unspun LipoTube or unseparated plain red-top or EDTA tube; serum or plasma specimen drawn in gel-barrier collection tube other than the NMR LipoTube; citrated plasma (light blue-top tube); hemolysis (may reduce GlycA concentrations more than 10%)
This "Extended Lipid Panel" quantifies the components of a typical lipid panel (TC, HDL-C and TG) along with ApoB by nuclear magnetic resonance (NMR) spectroscopy using the Vantera NMR Clinical Analyzer. Results from the Extended Lipid Panel Assay can be used by physicians to assist in CVD risk assessment. The principal protein component of LDL particles, ApoB, has been shown to be associated with CVD and is also an important CVD risk factor.
GlycA is hypothesized to be a nonspecific measure of global inflammation status. Unlike existing biomarkers of inflammation that are discrete molecular species, such as CRP or inflammatory cytokines, GlycA is a composite biomarker that integrates the protein levels and glycosylation states of several of the most abundant acute- phase proteins in serum. This allows for a more stable measure of systemic inflammation with lower intra-individual variability of GlycA than hsCRP. While guidelines recommend two serial measurements be taken at least two weeks apart when using hsCRP for CV disease risk assessment, only one measurement is necessary for evaluation of a patient's CV risk using the GlycA test.
The Diabetes Risk Index (DRI) is intended for use in adult subjects for the quantitative determination of a risk score in serum or plasma. The DRI score (1-100) may be used as an aid in stratifying the risk of developing type 2 diabetes in individuals with normo-glycemia or prediabetes. The Diabetes Risk Index (DRI) is a nuclear magnetic resonance spectroscopy (NMR)-derived multimarker score (values 1-100) that predicts a patient's risk of developing type 2 diabetes mellitus (T2D) independent of glycemic status. DRI derives its performance from the weighted addition of the Lipoprotein Insulin Resistance Index (LP-IR) scores with simultaneously-measured levels of branched-chain amino acids (BCAA).1-6
If triglyceride level is >800 mg/dL, LDL cholesterol will not be calculated.
GlycA measurements from EDTA plasma specimens are, on average, 3% to 5% lower than from serum samples. GlycA measurements from NMR LipoTube specimens are, on average, 5% to 6% higher than from serum samples collected in red-top tubes. DRI measurements from plasma specimens are on average 8 points lower than from serum specimens.
GlycA is an indicator for a wide range of disease processes and should not be interpreted without a complete clinical history. Recent medical events resulting in tissue injury, infections, or inflammation, which may cause elevated GlycA levels, should also be considered when interpreting results. Hemolysis may reduce GlycA concentrations more than 10%.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Nuclear magnetic resonance (NMR)
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|123567||Lipid Panel+ApoB+GlycA+DRI||123477||Cholesterol, Total||mg/dL||2093-3|
|123567||Lipid Panel+ApoB+GlycA+DRI||123478||Non-HDL Cholesterol||mg/dL||43396-1|
|123567||Lipid Panel+ApoB+GlycA+DRI||123479||LDL-C (NIH Calc)||mg/dL||13457-7|
|123567||Lipid Panel+ApoB+GlycA+DRI||123491||Apolipoprotein B||mg/dL||1884-6|
|123567||Lipid Panel+ApoB+GlycA+DRI||123856||Diabetes Risk Index (DRI)||94560-0|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf